Latest Research And Development News

dorsaVi Ltd is expanding its RRAM technology evaluation to next-generation robotics, aiming to deliver sub-millisecond reflexes that could revolutionize safety and dexterity in collaborative robots and wearables.

BPH Global has transitioned from development to early commercial sales in its Indonesian seaweed operations, securing key offtake agreements and advancing multiple R&D projects. The company also raised $609,000 in fresh capital, positioning itself for growth in sustainable biotech markets.

InFocus Group Holdings has secured a major $3.25 million contract to develop an advanced iGaming platform, while expanding its footprint with Chubb Life Assurance Thailand and other Southeast Asian clients.

Recce Pharmaceuticals advances its clinical pipeline with expanded Phase 3 trials in Indonesia and Australia, backed by a $15.8 million capital raise and a $30 million debt facility.

Advanced Health Intelligence Ltd has secured up to AUD 5.5 million from Oakley Capital Partners to support its ASX reinstatement and global growth ambitions, while targeting an additional USD 6 million from strategic investors and unlocking AUD 3 million in R&D grants.

Mount Ridley Mines advances its rare earth exploration strategy with a detailed tenement review and key board appointments, while maintaining a solid cash position at the end of June 2025.

Jayride Group has launched a new SaaS platform aimed at transforming its business model from a traditional aggregator to a scalable, subscription-based technology provider for ground transportation. Early integrations in Southeast Asia signal a strategic shift with promising growth potential.

Tungsten Mining NL advances its Mt Mulgine project with a new gold extraction approach while reporting a maiden inferred resource at Hatches Creek, positioning itself strongly amid rising tungsten prices.

Vectus Biosystems confirms safety of its lead fibrosis drug VB0004 from Phase Ia/Ib trials and advances licensing talks globally, including in China, while managing costs and funding challenges.

Papyrus Australia has made significant strides in Q2 2025, launching its Rapid Prototyping and R&D Facility and successfully trialling new banana fibre-based products, while deepening academic partnerships.

Argent BioPharma has achieved a significant milestone by commencing formal supply of its EU-GMP cannabinoid API for epilepsy treatment at a leading Slovenian hospital and gaining prescription approval for CannEpil™ in Germany, marking key steps in its European expansion.

State Gas Limited has successfully drilled two new wells at its Rolleston West Project, intersecting significant coal seams and initiating production testing, while engaging NSAI for independent reserve certification.